Compare Abeona Therapeutics Inc (ABEO) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs BioNano Genomics Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while BioNano Genomics Inc trades at $1.14 (market cap $13.08M). The key difference: Abeona Therapeutics Inc is far larger — about 28.5× BioNano Genomics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BNGO | |
|---|---|---|
Market Cap | $373.32M | $13.08M |
Sector | Health | Health |
52-Week High | $7.23 | $4.92 |
52-Week Low | $4.17 | $1.09 |
Enterprise Value | $228.22M | $15.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BNGO trades at $1.14, down 0.87% on the day, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported Q1 2026 revenue of $28.51M and a net loss of $26.40M, though it beat EPS estimates. Recent news includes leadership changes, debt retirement, and growing adoption of its optical genome mapping technology. Valuation ratios appear low with a P/E of 0.03 and P/S of 0.3, but profitability remains negative.
Outlook is cautiously optimistic due to improving cash flow trends and analyst support, but significant risks persist from ongoing losses and competitive pressures. The stock's near-term direction hinges on achieving profitability and sustaining revenue growth amid high operational costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
